Skip to content

Study · Randomized controlled trial · 1989

3 results

Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome.

Dodson WC, Hughes CL Jr, Yancy SE, Haney AF

Fertility and sterility1 Dec 1989Cited by 22 (Europe PMC)

PMID2512181 (opens in a new tab)DOI10.1016/s0015-0282(16)53151-3 (opens in a new tab)PepBankPUB-02512181
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, premature luteinization occurred less frequently with adjunctive leuprolide than with hMG alone.

    In plain wordsIn women with PCOS, adding leuprolide to hMG reduced premature luteinization compared with hMG alone.

    Peptide
    Leuprolide
    Outcome
    DecreasePremature luteinization
    Study

    n: not reported in source

    Comparator
    hMG alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Premature luteinization was seen less frequently in the leuprolide-treated cycles than in cycles treated with hMG alone.
    1 context sentence
    Summary · context
    In this prospective, randomized trial, 27 women with PCOS underwent a total of 25 cycles of hMG alone and 33 cycles with adjunctive GnRH-a (leuprolide) treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, ovarian sensitivity to hMG did not differ between adjunctive leuprolide and hMG alone.

    In plain wordsIn women with PCOS, adding leuprolide did not change ovarian sensitivity to hMG compared with hMG alone.

    Peptide
    Leuprolide
    Outcome
    No significant changeOvarian sensitivity to hMG
    Study

    n: not reported in source

    Comparator
    hMG alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were no differences between the treatments in ovarian sensitivity to hMG.
    1 context sentence
    Summary · context
    In this prospective, randomized trial, 27 women with PCOS underwent a total of 25 cycles of hMG alone and 33 cycles with adjunctive GnRH-a (leuprolide) treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, cycle fecundity was 0.27 with leuprolide plus hMG versus 0.16 with hMG alone, without statistical significance.

    In plain wordsIn women with PCOS, cycle fecundity was 0.27 with added leuprolide versus 0.16 with hMG alone, without statistical significance.

    Peptide
    Leuprolide
    Outcome
    IncreaseCycle fecundity
    Study

    n: not reported in source

    Comparator
    hMG alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Cycle fecundity
    0.27
    leuprolide with hMG
    Cycle fecundity
    0.16
    hMG alone

    Source sentences

    Summary
    Cycle fecundity was 0.16 for hMG alone cycles, and 0.27 for leuprolide with hMG cycles, which were not statistically different.
    1 context sentence
    Summary · context
    In this prospective, randomized trial, 27 women with PCOS underwent a total of 25 cycles of hMG alone and 33 cycles with adjunctive GnRH-a (leuprolide) treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.